Substituted anilinic piperidines as MCH selective antagonists
This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
1. A compound having the structure:
wherein W is
wherein R 1 is hydrogen, straight chained or branched C 1 –C 7 alky, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one or more —F, —Cl, —Br, —CN, —NO 2 , —OCH 3 , —CO 2 CH 3 , —CF 3 , phenyl, straight chained or branched C 1 –C 7 alkyl;
wherein R 2 is straight-chained or branched C 3 –C 4 alkyl or cyclopropyl;
wherein A is —H, —F, —Cl, —Br, —CN, —NO 2 , —COR 1 , —CO 2 R 1 , straight chained or branched C 1 –C 7 alkyl, monofluoroalkyl or polyfluoroalkyl or phenyl;
wherein each B is independently —H, —F, —Cl, —Br, —I, —CN, —NO 2 , —COR1, —CO 2 R1, —OCH 3 , —OCF 3 , —CF 3 , straight chained or branched C 1 –C 7 alkyl, monofluoroalkyl or polyfluoroalkyl or aryl, phenoxy or benzyloxy, wherein the aryl, phenoxy or benzyloxy is optionally substituted with one or more —F, —Cl, —Br, —CN, —NO 2 , —COR 1 , —CO 2 R 1 , —OCH 3 , —OCF 3 , —CF 3 or straight chained or branched C 1 –C 7 alkyl.
2. The compound of claim 1 , wherein W is
3. The compound of claim 2 , wherein R 1 is hydrogen or phenyl optionally substituted with one or more —F, —Cl, —Br, —CN, —NO 2 , straight chained or branched C 1 –C 7 alkyl.
4. The compound of claim 3 , wherein R 2 is isopropyl.
5. The compound of claim 4 , wherein the compound has the structure:
6. The compound of claim 4 , wherein the compound has the structure:
7. A process for making a pharmaceutical composition comprising admixing a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
9. A method of treating a subject suffering from a disorder selected from the group consisting of depression, anxiety, urge incontinence, or obesity comprising administering to the subject a therapeutically effective amount of a compound of claim 1 .
10. The method of claim 9 , wherein the disorder is anxiety.
11. The method of claim 9 , wherein the disorder is obesity.
12. The method of claim 9 , wherein the disorder is urge incontinence.